glp-1 compounding news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Warns 25 Firms Over

In MM patients, 24% of tumors exhibit copy number loss of CDKN2A ( CDK4 , CCND1 , and MDM2 are amplified in 28%, 18%, and 19% of samples respectively, and TP53 mutations occur in 9.0% of MMs ( CDKN2A loss than MM, MM tends to show a greater frequency of CCND1 and CDK4 amplification (120, 122), implying CDK4 blocking agents may achieve a desired anti-tumor effect on MM

And the superstar, vitamin B12, adds that extra kick to keep your energy levels high

Our formulations utilize advanced liposomal delivery for optimal bioavailability, ensuring that your body can absorb and utilize the antioxidants effectively

Reductions in A1c levels were similar in any duration of diabetes in DUAL-1 and 2

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model Ann Clin Lab Sci, 2015, cartilage-repair and osteoarthritis model PMID 25208511 Cox HD et al